产品说明书

SGN-2FF

Print
Chemical Structure| 2089647-47-0 同义名 : 2-fluorofucose
CAS号 : 2089647-47-0
货号 : A1364779
分子式 : C6H11FO4
纯度 : 98%
分子量 : 166.148
MDL号 : N/A
存储条件:

粉末 Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(300.94 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 35 mg/mL(210.66 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 Fucosylation is the process of adding fucose sugar units to a molecule. It is a type of glycosylation. SGN-2FF is an orally bioavailable small-molecule inhibitor of glycoprotein fucosylation that has potential to enhance immune-mediated antitumor activity[1]. SGN-2FF treatment of nude mice, which maintain functional B cells and antibody production, resulted in a delay in LS174T tumor growth compared with untreated mice. The antitumor effect of SGN-2FF in syngeneic mouse model appeared to be dependent on T cell activity. Preclinical assays were applied in patient samples and results showed cell surface fucosylation on granulocytes was significantly reduced and neutrophil count was significantly increased in 6 of 7 treated subjects[2].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

6.02mL

1.20mL

0.60mL

30.09mL

6.02mL

3.01mL

60.19mL

12.04mL

6.02mL

参考文献

[1]Do, K.T., Chow, L.Q.M., Reckamp, K., Sanborn, R.E., Burris, H., Robert, F., Camidge, D.R., Steuer, C.E., Strickler, J.H., Weise, A., Specht, J.M., Gutierrez, M., Haughney, P., Hengel, S., Derleth, C.L. and Yap, T.A. (2021), First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. The Oncol, 26: 925-e1918.

[2]Nicole M. Okeley, Ryan A. Heiser, Weiping Zeng, Shawna Mae Hengel, Jason Wall, Peter C. Haughney, Timothy Anthony Yap, Francisco Robert, Rachel E. Sanborn, Howard Burris, Laura Q. Chow, Khanh T. Do, Martin Gutierrez, Karen Reckamp, Amy Weise, D Ross Camidge, John Strickler, Conor Steuer, Zejing Wang, Megan M. O'Meara, Stephen C. Alley, Shyra J. Gardai; Abstract 5551: SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis. Cancer Res 1 July 2018; 78 (13_Supplement): 5551.